Liquid biopsy enters the clinic—implementation issues and future challenges
Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …
cells in peripheral blood have provided crucial insights into cancer biology and the …
The lingering mysteries of metastatic recurrence in breast cancer
Despite being the hallmark of cancer that is responsible for the highest number of deaths,
very little is known about the biology of metastasis. Metastatic disease typically manifests …
very little is known about the biology of metastasis. Metastatic disease typically manifests …
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
D Kotani, E Oki, Y Nakamura, H Yukami, S Mishima… - Nature medicine, 2023 - nature.com
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …
Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update
F Andre, N Ismaila, KH Allison, WE Barlow… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To update recommendations on appropriate use of breast cancer biomarker
assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast …
assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast …
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with
cancer. However, existing biomarkers do not reliably predict treatment response across …
cancer. However, existing biomarkers do not reliably predict treatment response across …
Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
Cancer evolution: Darwin and beyond
Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …
[HTML][HTML] Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment
via non-invasive tumor burden assessment. To investigate subtype-specific differences in …
via non-invasive tumor burden assessment. To investigate subtype-specific differences in …
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
Neoantigens arising from mutations in tumor DNA provide targets for immune-based
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …